StriVectin Revises Ad With NAD-Approved ‘Clear And Conspicuous’ Disclosure
This article was originally published in The Rose Sheet
Executive Summary
The National Advertising Division continues work by the FTC in 2014 to crack down on inadequate disclosures, inquiring into a disclaimer used in print advertising for StriVectin Intensive Illuminating Serum. The skin-care firm will use a revised ad going forward that addresses NAD’s concerns about the disclaimer’s placement, clarity and conspicuousness.